Article
Eight weeks of Paritaprevir/r/Ombitasvir + Dasabuvir in HCV genotype 1b with mild-moderate fibrosis: Results from a real-world cohort.
Liver international : official journal of the International Association for the Study of the Liver - 1 Jan 2019
Puigvehí Marc, De Cuenca Beatriz, Viu Ana, Diago Moisés, Turnes Juan, Gea Francisco, Pascasio Juan M, Lens Sabela, Cabezas Joaquín, Badia Ester, Olveira Antonio, Morillas Rosa M, Torras Xavier, Montoliu Silvia, Cordero Patricia, Castro José L, Salmerón Javier, Molina Esther, Sánchez-Ruano Juan J, Moreno Javier, Antón María D, Moreno José M, De la Vega Juan, Calleja José L, Carrión José A
Abstract excerpt
BACKGROUND & AIMS: The interferon-free regimen paritaprevir/ritonavir, ombitasvir + dasabuvir (PTV/r/OBV/DSV) has shown high efficacy in patients with hepatitis C virus (HCV) genotype 1b infection when administered for 8 or 12 weeks, but data regarding the 8-week treatment are scarce. The aim of our study was to assess the efficacy and safety of the 8-week administration of PTV/r/OBV/DSV in a real-world cohort....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.